Display options
Cite
Cholkar K, Gilger BC, Mitra AK. Topical, Aqueous, Clear Cyclosporine Formulation Design for Anterior and Posterior Ocular Delivery. Transl Vis Sci Technol. 2015;4(3):1doi: 10.1167/tvst.4.3.1.
Cholkar, K., Gilger, B. C., & Mitra, A. K. (2015). Topical, Aqueous, Clear Cyclosporine Formulation Design for Anterior and Posterior Ocular Delivery. Translational vision science & technology, 4(3), 1. https://doi.org/10.1167/tvst.4.3.1
Cholkar, Kishore, et al. "Topical, Aqueous, Clear Cyclosporine Formulation Design for Anterior and Posterior Ocular Delivery." Translational vision science & technology vol. 4,3 (2015): 1. doi: https://doi.org/10.1167/tvst.4.3.1
Cholkar K, Gilger BC, Mitra AK. Topical, Aqueous, Clear Cyclosporine Formulation Design for Anterior and Posterior Ocular Delivery. Transl Vis Sci Technol. 2015 May 01;4(3):1. doi: 10.1167/tvst.4.3.1. eCollection 2015 May. PMID: 25964868; PMCID: PMC4418434.
Copy Download .nbib Format: NLM
Share it on

Transl Vis Sci Technol. 2015 May 01;4(3):1. doi: 10.1167/tvst.4.3.1. eCollection 2015 May.

Topical, Aqueous, Clear Cyclosporine Formulation Design for Anterior and Posterior Ocular Delivery.

Translational vision science & technology

Kishore Cholkar, Brian C Gilger, Ashim K Mitra

PMID: 25964868 PMCID: PMC4418434 DOI: 10.1167/tvst.4.3.1

Abstract

PURPOSE: The main objective of this study was to optimize cyclosporine (CsA) nanomicellar solution and study in vivo ocular CsA tissue distribution with a topical drop.

METHODS: An optimized blend of hydrogenated castor oil-40 and octoxynol-40 was prepared to entrap CsA within nanomicelles. In vivo studies were conducted in New Zealand White albino rabbits with topical drop instillation.

RESULTS: Average size of CsA-loaded nanomicelles was approximately 22.4 nm. Ocular tissue CsA quantification with single and multiple dosing revealed that CsA levels followed as cornea → iris-ciliary body → aqueous humor → lens. Cyclosporine levels were also found to be in the following order: conjunctiva → sclera → retina/choroid → vitreous humor. High CsA level was detected in retina/choroid (53.7 ng/g tissue).

CONCLUSIONS: Ocular tissue CsA distribution studies revealed high CsA concentrations in anterior ocular tissues. Moreover, it appears that nanomicelles are transported through a conjunctival-scleral pathway and deliver CsA to the retina/choroid. Results suggest polymeric blend to be a safe carrier for anterior and posterior ocular tissues.

TRANSLATIONAL RELEVANCE: This study has significant translational relevance, disclosing results that suggest that aqueous nanomicellar approach can provide high corneal and conjunctival CsA concentrations. Aqueous nanomicelles can deliver high drug concentrations not only to anterior but also to back of the eye tissues, including retina. This article provides a platform for noninvasive back of the eye drug delivery with topical eye drops. Aqueous CsA nanomicelles have no perceptible toxicity such as cell membrane damage or cytotoxicity to corneal and retinal pigment epithelial cells. Clear aqueous nanomicellar solution can be translated to human conditions for keratoconjunctivitis sicca and other anti-inflammatory conditions.

Keywords: back of the eye; cyclosporine; drops; drug delivery; dry eye; formulation; nanomicelles; posterior; rabbits; retina/choroid; sclera; topical

References

  1. J Ocul Pharmacol Ther. 2011 Feb;27(1):23-7 - PubMed
  2. Surv Ophthalmol. 2009 May-Jun;54(3):321-38 - PubMed
  3. AAPS PharmSciTech. 2015 Jun;16(3):610-22 - PubMed
  4. Immunopharmacology. 2000 May;47(2-3):119-25 - PubMed
  5. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S41-52 - PubMed
  6. Mol Vis. 2012;18:2195-204 - PubMed
  7. Arch Ophthalmol. 2002 Mar;120(3):330-7 - PubMed
  8. Biomacromolecules. 2007 Jan;8(1):202-8 - PubMed
  9. AAPS PharmSciTech. 2014 Dec;15(6):1454-67 - PubMed
  10. J Ocul Pharmacol Ther. 2010 Apr;26(2):157-64 - PubMed
  11. Recent Pat Nanomed. 2012;2(2):82-95 - PubMed
  12. J Ocul Pharmacol Ther. 2009 Dec;25(6):487-98 - PubMed
  13. J Ocul Pharmacol Ther. 2013 Mar;29(2):106-23 - PubMed
  14. Int J Pharm. 2010 Mar 30;388(1-2):107-13 - PubMed
  15. Cornea. 1993 Jul;12(4):315-23 - PubMed
  16. Int J Mol Sci. 2010;11(12 ):5256-72 - PubMed
  17. Eur J Pharm Biopharm. 2011 Jan;77(1):56-65 - PubMed
  18. Invest Ophthalmol Vis Sci. 2012 Apr 30;53(4):2292-9 - PubMed
  19. Curr Eye Res. 2015 May;40(5):457-69 - PubMed
  20. Optom Vis Sci. 2008 Aug;85(8):715-25 - PubMed
  21. Adv Drug Deliv Rev. 2009 Jun 21;61(6):438-56 - PubMed
  22. Curr Eye Res. 1999 Feb;18(2):91-103 - PubMed
  23. Invest Ophthalmol Vis Sci. 1996 Dec;37(13):2686-93 - PubMed
  24. Pharmazie. 2008 Mar;63(3):171-9 - PubMed
  25. Acta Ophthalmol (Copenh). 1994 Aug;72(4):438-42 - PubMed

Publication Types

Grant support